Skip to content

The efficacy and safety of 1565nm non-ablative fractional laser and 1064nm picosecond fractional laser in the treatment of striae gravidarum: a self-controlled study

The efficacy and safety of 1565nm non-ablative fractional laser and 1064nm picosecond fractional laser in the treatment of striae gravidarum: a self-controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084578
Enrollment
Unknown
Registered
2024-05-21
Start date
2024-05-27
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy White Striae

Interventions

treatment group 1:1565nm non-ablative fractional laser
treatment group 2:1064nm picosecond fractional laser

Sponsors

The Second Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
22 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1)The pregnancy white striae, bilateral and symmetrical on the abdomen, stable for over one year; (2) Age 22-45 years old; (3) Subjects are able to fully understand and sign the informed consent form, and receive treatment and follow-up according to the protocol.

Exclusion criteria

Exclusion criteria: ? Individuals with a tendency for hypertrophic scarring; (2) Those with active dermatological conditions in the treatment area, such as herpes simplex, herpes zoster, folliculitis, etc; (3) Patients prone to isomorphic reactions, such as those with psoriasis, vitiligo, flat warts, etc; (4) Individuals with implanted metal devices on the skin surface; (5) Patients with a history of abnormal pigmentation in the treatment area prior to therapy; (6) Those with a history of diseases affecting wound healing or poor skin healing ability; (7) Individuals using topical corticosteroid creams on the abdomen within two weeks prior to treatment; (8) Recent significant weight fluctuations; (9) Patients who have taken retinoic acid medications within the past month; (10) Individuals currently using corticosteroids, anticoagulants, or any medication causing photosensitivity reactions; (11) Pregnant women; (12) Those with a history of psychiatric disorders; (13) Recent history of major surgeries; (14) Patients with a history of pacemakers or other implanted devices; (15) Patients with unrealistic expectations or uncooperative behavior; (16) Individuals who have undergone other treatments for stretch marks within the past six months; (17) Allergic to compound lidocaine cream.

Design outcomes

Primary

MeasureTime frame
Clinical efficacy;Patient satisfaction;

Secondary

MeasureTime frame
Pain;Pigmentation;High-frequency ultrasound examination;skin biopsy;Measurement of the width of stretch marks;

Countries

China

Contacts

Public ContactXiao rong

The Second Xiangya Hospital, Central South University

xiaorong65@csu.edu.cn+86 138 0842 5555

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026